Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina Inc (NASDAQ: ILMN) is described by the company as a global leader in DNA sequencing and array-based technologies, serving research, clinical, and applied markets across genomics, multiomics, and proteomics. This news page aggregates recent press releases and announcements so readers can follow how Illumina’s technologies, collaborations, and financial disclosures evolve over time.
Company news highlights include product and platform launches, such as Illumina Connected Multiomics, a cloud-based software platform for analyzing and visualizing multiomic data, and Illumina Protein Prep, which the company states delivers broad coverage of the blood proteome and supports large-scale genomics studies. Illumina has also announced the Illumina Billion Cell Atlas, a large genome-wide genetic perturbation dataset developed through its BioInsight business to support AI-driven drug discovery in collaboration with pharmaceutical partners.
Investors can use this news feed to track Illumina’s preliminary financial results, earnings announcements, and capital markets activities, as reflected in press releases tied to quarterly and annual results and conference presentations. The page also captures updates on strategic agreements and acquisitions, including Illumina’s planned acquisition of Standard BioTools’ aptamer-based and functional proteomics business, as described in SEC filings and related communications.
In addition, Illumina’s news often covers leadership appointments, regulatory and market developments, and collaborations with genomics and population health partners such as MyOme. By reviewing these updates in one place, readers can better understand how Illumina positions its sequencing, multiomic, and proteomic offerings and how its corporate strategy and partnerships may influence its role in genomics and precision medicine. Bookmark this page to review new company-issued information as it becomes available.
Illumina, Inc. (NASDAQ: ILMN) announced it will appeal the Federal Trade Commission's decision requiring the unwinding of its acquisition of GRAIL. The company plans to file a petition for review with the US Court of Appeals, seeking expedited treatment. The FTC's order will remain stayed during the appeal process. Illumina believes it has a strong case following a favorable ruling from an ALJ in September 2022. Successful appeals are expected to enhance shareholder value by expanding the market for the Galleri test, projected at over $44 billion. If the company loses the appeal, it will expedite divestiture of GRAIL to protect shareholder interests.
On March 30, 2023, Illumina (NASDAQ: ILMN) filed a preliminary proxy statement with the SEC, highlighting the upcoming shareholder vote at the 2023 Annual Meeting. Activist investor Carl Icahn has nominated three associates for Board positions, which Illumina strongly opposes, citing a lack of relevant skills. The company believes Icahn's involvement poses risks to its long-term success. Despite attempts to engage with Icahn and his nominees, the company found their proposals lacking substance. Illumina urges shareholders to vote in favor of its current Board and to disregard Icahn's proxy card, emphasizing the importance of informed voting.
Illumina, a leader in DNA sequencing, has launched Connected Insights, a cloud-based software for tertiary analysis of clinical next-generation sequencing (NGS) data, aimed at improving precision care. Announced on March 27, 2023, this new tool streamlines data interpretation and enhances reporting processes, particularly for somatic oncology applications. Connected Insights connects labs to over 45 third-party knowledge sources, helping to manage genomic data effectively. Currently, the software is commercially available in select countries and undergoing beta testing in the US, catering to the increasing demand for NGS testing in the healthcare sector.
Illumina, Inc. (NASDAQ: ILMN) issued a statement on March 24, 2023, in response to a letter from Carl Icahn. The company emphasized that Directors and Officers (D&O) insurance is standard and supports directors in making shareholder-focused decisions. Illumina's Board of Directors is independent, acts in shareholders' interests, and follows strict risk management practices. The company dismissed Icahn's nominees, citing a lack of relevant skills. The statement also included forward-looking statements regarding business performance and highlighted risks, including the ongoing legal issues related to the acquisition of GRAIL.
Illumina (NASDAQ: ILMN) issued a response to Carl Icahn's recent public statements asserting its commitment to maximizing shareholder value. The company highlighted its successful track record of profitability and innovation, including the launch of the highly demanded NovaSeq™ X and the performance of GRAIL's Galleri™ cancer detection test, which generated $55 million in 2022 and is projected to reach $90-110 million in 2023. Illumina's Board maintains that Icahn's proposed nominees lack relevant expertise, potentially jeopardizing the company's core value. With a robust installed base and ongoing cost management strategies, Illumina is well-positioned for long-term growth in the genomics sector.
Illumina Inc. (NASDAQ: ILMN) has launched its Illumina Complete Long Read Prep, Human, a groundbreaking long-read human whole-genome sequencing assay. This product revolutionizes DNA sequencing by enabling both long- and short-read data from the same instrument, with remarkably reduced DNA input requirements compared to traditional long-read technologies. Priced at $1,350 USD per whole genome, it promises enhanced accuracy and streamlined workflows, backed by early customer feedback showcasing a 99.87% accuracy rate. This advancement supports genetic disease research and offers a pathway for future applications beyond whole-genome sequencing.
Illumina (Nasdaq: ILMN) announced that it received a notice from Icahn Partners LP regarding the nomination of three candidates for its Board of Directors ahead of the 2023 Annual Meeting of Shareholders. The nominees include two current employees and a former employee of Icahn. Illumina's Board expressed that these nominees lack relevant skills and recommended shareholders not support their election. The Board remains independent and is committed to enhancing shareholder value. Illumina is also addressing regulatory requirements concerning divestiture and continues to focus on innovative products like the NovaSeq X to support its customers.
Illumina supports innovative research at Children's Mercy Kansas City, focusing on pediatric cancer complexities. With 390 inpatient beds and 14,345 admissions in 2022, the hospital established the Children's Mercy Research Institute in 2015. Their Genomic Answers for Kids program aims to sequence 30,000 children, providing over 1,000 rare disease diagnoses. They conduct 137 studies, including 49 in oncology, and have a biobank for pediatric oncology samples. A new clinical exome test for children diagnosed with cancer allows paired tumor/normal testing, enhancing treatment precision.
Illumina has launched a new genomic initiative aimed at conserving endangered elephants in Africa, partnering with experts from various organizations to create a genomic atlas that tracks elephant diversity. The IUCN reports a stark 86% decline in African forest elephants, with habitat loss and poaching as major threats. This initiative utilizes over 400 historical biological samples to sequence whole genomes, providing crucial insights into genetic diversity and population dynamics. The project aims to empower local conservationists by developing practical tools for field analysis and fostering coexistence strategies between humans and elephants.
Illumina emphasizes its commitment to addressing rare diseases during Rare Disease Day 2023. The company spotlighted four key organizations: ARGAD, Taiwan Foundation for Rare Disorders, To Cure a Rose Foundation, and Tanzania Human Genetics Organization, each enhancing patient care and advocacy. Illumina's iHope program has provided pro bono genome testing to 1,700 children, with 40% receiving diagnoses. Recently, iHope expanded to China, set to aid over 2,000 patients. Furthermore, Illumina plans to improve global access to genome testing via the iHope Genetic Health initiative, supported by a $120 million donation, benefiting 50,000 patients yearly over five years.